miRNA在异丙肾上腺素诱导大鼠心肌肥厚中的表达及生物信息学分析*

doi:10.12047/j.cjap.5835.2019.104

摘要/Abstract

摘要： 目的:探讨miRNAs(miR199a-5P、miR206、miR133a-3P、miR499-5P)在异丙肾上腺素(ISO)诱导大鼠心肌肥厚模型组中的表达变化;并运用生物信息学方法分析相关的主要信号通路及分子机制。方法:将16只SD雄性大鼠随机分为2组:对照组和ISO模型组,模型组给予ISO(1 mg/kg)诱导心肌肥厚模型,对照组给予等量生理盐水,均采用背部皮下多点注射。连续给药10 d后采用超声心动图测量舒张期室间隔厚度(IVSd)、舒张期左室后壁厚度(LVPWd)、左室舒张末期内径(LVDd)及心脏收缩功能(EF%);称量心脏重量(HW)、大鼠体重(BW),并计算心脏/体重比(HW/BW);心肌组织HE染色,Image J分析软件测量心肌细胞表面积;RT-qPCR检测大鼠心肌组织中4种miRNAs的表达情况。运用Targetscan、miRDB、miRwalk 数据库预测大鼠4种miRNAs可能的靶基因,FunRich软件分析预测靶基因相关的信号通路。结果:与正常组相比,模型组IVSd、LVPWd增厚,LV增大,EF%明显降低;HW、HW/BW增加;模型组心肌细胞体积明显增大,排列紊乱,细胞表面积增加;模型组miR199a-5P、miR206表达上调(P＜0.05);miR133a-3P、miR499-5P表达下调(P＜0.05)。应用生物信息学预测4种miRNAs的靶基因可能参与心肌肥厚相关的信号通路主要有:VEGF/VEGFR信号通路、ErbB受体信号通路等。结论:ISO诱导心肌肥厚导致miRNAs表达的改变,生物信息学预测4种miRNAs参与心肌肥厚相关的靶基因及其主要信号通路,这些研究为心肌肥厚的调控机制及其防治措施提供了新思路。

关键词: 异丙肾上腺素, miRNAs, 心肌肥厚, 生物信息学, 大鼠

Abstract: Objective: To investigate the expression changes of miRNAs (miR199a-5P, miR206, miR133a-3P, miR499-5P) in rat model of cardiac hypertrophy induced by isoproterenol (ISO), and to explore the main signal pathways and molecular mechanisms which related to that with the way of bioinformatics. Methods: Sixteen SD male rats were randomly divided into two groups: control group and ISO model group. The rats in model group were treated with ISO (1 mg/kg) to induce cardiac hypertrophy, the rats in control group were treated with the same amount of saline, and all were injected subcutaneously at the back. After 10 days of continuous administration, interventricular septal thickness at diastole (IVSd), left ventricular posterior wall thickness at diastole (LVPWd) , left ventricular end-diastolic diameter(LVDd), and systolic function (EF%) were measured by echocardiography. Heart weight (HW) and rat body weight (BW) were weighed, and heart/body weight ratio (HW/BW) was calculated. Myocardial tissues were stained with HE, and myocardial cell surface area was measured by Image J analysis software; RT-qPCR was used to detect the expressions of 4 miRNAs in rat myocardial tissues. Targetscan, miRDB and miRwalk databases were used to predict the possible target genes of four kinds of miRNAs in rats, and FunRich software was used to analyze and predict the signal pathways related to the target genes. Results: Compared with the control group, the IVSd and LVPWd in the model group were thickened, the LV was increased, and the EF% was decreased significantly. The HW and HW/BW were increased. The myocardial cell volume in the model group was increased significantly, the arrangement was disordered, and the cell surface area was increased; the expressions of miR199a-5P and miR206 in the model group were up-regulated by RT-qPCR (P＜0.05); the expressions of miR133a-3P and miR499-5P were down-regulated (P＜0.05). Predicted by bioinformatics application, related signal pathways which target genes of 4 miRNAs maybe involved in cardiac hypertrophy mainly are: VEGF/VEGFR signal pathway, ErbB receptor signal pathway and other signal pathways. Conclusion: ISO-induced cardiac hypertrophy leads to changes in miRNA expression, and bioinformatics predicts related target genes of four miRNAs involved in cardiac hypertrophy and their major signaling pathways. These studies will provide new ideas for the regulation of cardiac hypertrophy and its prevention and treatment measures.

Key words: isoproterenol, miRNAs, cardiac hypertrophy, bioinformatics, rat

伍学翠, 赵云, 李聪, 熊海容, 郑智维, 周军, 刘蓉, 龚威, 刘朝奇. miRNA在异丙肾上腺素诱导大鼠心肌肥厚中的表达及生物信息学分析^*[J]. 中国应用生理学杂志, 2019, 35(5): 476-480.

WU Xue-cui, ZHAO Yun, LI Cong, XIONG Hai-rong, ZHENG Zhi-wei, ZHOU Jun, LIU Rong, GONG Wei, LIU Chao-qi. Expression and bioinformatics analysis of miRNA in ISO-induced rat cardiac hypertrophy[J]. CJAP, 2019, 35(5): 476-480.

参考文献

[1] Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics-2018 update: A report from the American Heart Association[J]. Circulation, 2018, 137(12): e67－e492.
[2] Bartel DP. MicroRNAs: Target recognition and regulatory functions[J]. Cell, 2009, 136(2): 215-233.
[3] Sayed D, Hong C, Chen IY, et al. MicroRNAs play an essential role in the development of cardiac hypertrophy[J]. Circ Res, 2007, 100(3): 416-424.
[4] Cheng Y, Ji R, Yue J, et al. MicroRNAs are aberrantly expressed in hypertrophic heart: do they play a role in cardiac hypertrophy[J]? Am J Pathol, 2007, 170(6): 1831-1840.
[5] Zhang R, Dong DL, Yang BF. Basic research and application of microRNA--a novel target for regulating cardiac arrhythmias[J]. Acta Pharm Sinica, 2011, 46(1): 6-11.
[6] Condorelli G, Latronico M V G, Ii G W D. microRNAs in heart disease: putative novel therapeutic targets[J]? Eur Heart J, 2016, 31(6): 649-658.
[7] 程杰坤, 孙小慧, 高莉萍, 等. 法舒地尔对异丙肾上腺素诱导大鼠心肌肥厚的干预作用及其机制[J]. 中国应用生理学杂志, 2016, 32(5): 414-418.
[8] 王羽, 刘明洁, 付瑶, 等. 苏格木勒-3汤对异丙肾上腺素诱导的大鼠心肌肥厚Caspase3/9表达的影响[J]. 中国应用生理学杂志, 2017, 33(5): 390-392.
[9] 徐峰, 王景全, 白小涓, 等. 高频超声显像评价慢性压力负荷大鼠心肌结构和功能的动态变化[J]. 中华医学杂志(英文版), 2002, 115(4): 487-490.
[10]Dong DL, Yang BF. Role of microRNAs in cardiac hypertrophy, myocardial fibrosis and heart failure[J]. Acta Pharm Sinica B, 2011, 1(1): 1-7.
[11]Wang J, Yang X. The function of miRNA in cardiac hypertrophy[J]. Cell Mol Life Sci, 2012, 69(21): 3561-3570.
[12]Gao J, Li YH, Wang TM, et al. Analyzing gene expression profiles with preliminary validations in cardiac hypertrophy induced by pressureoverload[J]. Can J Physiol Pharmacol, 2018, 96(8): 701-709.
[13]Zhang H, Li S, Zhou Q, et al. Qiliqiangxin attenuates phenylephrine-induced cardiac hypertrophy through downregulation of MiR-199a-5p[J]. Cell Physiol Biochem, 2016, 38(5): 1743-1751.
[14]Rane S, He M, Sayed D, et al. An antagonism between the AKT and beta-adrenergic signaling pathways mediated through their reciprocal effects on miR-199a-5p[J]. Cell Signal, 2010, 22(7): 1054-1062.
[15]Yang Y, Re D p D, Nakano N, et al. miR-206 mediates YAp-induced cardiac hypertrophy and survival[J]. Circ Res, 2015, 117(10): 891-904.
[16]Shieh J T C , Huang Y, Gilmore J, et al. Elevated miR-499 levels blunt the cardiac stress response[J]. PLoS ONE, 2011, 6.
[17]吴扬, 郭媛媛, 张元媛, 等. H2S对大鼠心肌肥大与miRNA-133a和Ca2+/CaN/NFATc4信号通路的影响[J]. 中国应用生理学杂志, 2018, 34(1): 29-34.
[18]Shen J, Xie Y, Liu ZJ, et al. Increased myocardial stiffness activates cardiac microvascular endothelial cell via VEGF paracrine signaling in cardiac hypertrophy[J]. J Mol Cell Cardiol, 2018, 122: 140-151.
[19]Xu XH, Xu J, Xue L, et al. VEGF attenuates development from cardiac hypertrophy to heart failure after aortic stenosis through mitochondrial mediated apoptosis and cardiomyocyte proliferation[J]. J Cardiothorac Surg, 2011, 6(1): 54-62.
[20]Wang T, Li R, Lin C, et al. Copper suppression of vascular endothelial growth factor receptor-2 is involved in the regression of cardiomyocyte hypertrophy[J]. Exp Biol Med, 2014, 239(8): 948-953.
[21]Zou Y, Lin L, Ye Y, et al. Qiliqiangxin inhibits the development of cardiac hypertrophy, remodeling, and dysfunction during 4 weeks of pressure overload in mice [J]. J Cardiovasc Pharmacol, 2012, 59(3): 268-280.
[22]Li Z, Song Y, Liu L, et al. miR-199a impairs autophagy and induces cardiac hypertrophy through mTOR activation[J]. Cell Death Differ, 2017, 24(7): 1205-1213.
[23]Yan W, Guo L R, Zhang Q, et al. Chronic blockade of class I PI3-kinase attenuates Ang II-induced cardiac hypertrophy and autophagic alteration[J]. Eur Revr Med Pharmaco, 2015, 19(5): 772-783.
[24]Ferdous A, Battiprolu PK, Ni YG, et al. FoxO, autophagy, and cardiac remodeling[J]. J Cardiovasc Trans Res, 2010, 3(4): 355-364.
[25]Rifki O F, Hill J A . Cardiac autophagy: good with the bad[J]. J Cardiovasc Pharmacol, 2012, 60(3): 248-252.
[26]Lucas E, Vila-Bedmar R, Arcones AC, et al. Obesity-induced cardiac lipid accumulation in adult mice is modulated by G protein-coupled receptor kinase 2 levels[J]. Cardiovascular Diabetology, 2016, 15(1): 155-168.
[27]Kolwicz SC, Tian R .Glucose metabolism and cardiac hypertrophy[J]. Cardiovascular Research, 2011, 90(2): 194-201.
[28]Zhang C, Wang F, Zhang Y, et al. Celecoxib prevents pressure overload-induced cardiac hypertrophy and dysfunction by inhibiting inflammation, apoptosis and oxidative stress[J]. J Cell Mol Med, 2016, 20(1): 116-127.

miRNA在异丙肾上腺素诱导大鼠心肌肥厚中的表达及生物信息学分析^*

Expression and bioinformatics analysis of miRNA in ISO-induced rat cardiac hypertrophy

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	扈敬, 李法东, 邵小婷, 李思葳, 张欣颖, 赵冰冰, 徐长庆, 魏璨. 精胺对高糖引起的大鼠心肌纤维化的影响及其机制[J]. 中国应用生理学杂志, 2020, 36(3): 193-196.
[2]	朱建忠, 赵灿, 隋月林, 刘媛媛, 乔跃兵. 瘦素对糖尿病大鼠糖脂代谢及炎性因子的影响[J]. 中国应用生理学杂志, 2020, 36(3): 197-201.
[3]	孙晓娟, 冯武龙, 侯娜, 李娜, 姜蔚丽. 有氧运动和白藜芦醇对2型糖尿病大鼠肾脏JAK2及TGF-β1的影响[J]. 中国应用生理学杂志, 2020, 36(3): 202-206.
[4]	石慧, 梁晓珊, 黄丽文, 罗之刚, 谭龙. 一种高尿酸血症大鼠模型诱导方法的改良和效果评价研究[J]. 中国应用生理学杂志, 2020, 36(3): 223-227.
[5]	杨琼, 潘娅, 陈粲, 戴桃李. 阿尼西坦对血管性痴呆大鼠的治疗作用[J]. 中国应用生理学杂志, 2020, 36(3): 232-234.
[6]	韩洁, 刘子怡, 方振, 田蕾, 杨丹凤, 袭著革, 刘晓华. 重复制动应激对雌性大鼠下丘脑-垂体-卵巢轴的影响[J]. 中国应用生理学杂志, 2020, 36(3): 245-249.
[7]	孙景然, 樊祢祢, 张桢, 吴瑾, 韩殿鹏, 白家磊, 杜连群, 房彦军. 有机磷阻燃剂TDCIPP对雌性大鼠甲状腺的潜在毒性作用[J]. 中国应用生理学杂志, 2020, 36(3): 250-254.
[8]	陈宇峰, 董凡赫, 楼云玮, 寿今豪, 张慧婷, 周一超, 严明, 毛红娇, 张云. 补骨脂素对TCP磨损颗粒所致大鼠成骨细胞损伤的干预作用及其机制[J]. 中国应用生理学杂志, 2020, 36(3): 255-260.
[9]	李家卉, 张敏, 付子豪, 李勇枝, 王佳平, 高峰, 董玲. 经皮穿刺抽取大鼠脑脊液方法的改良[J]. 中国应用生理学杂志, 2020, 36(3): 265-267.
[10]	徐昌顺, 孙培, 林春. 改良型大鼠鞘内穿刺置管针及导管末端注药装置在大鼠鞘内置管术中的应用研究[J]. 中国应用生理学杂志, 2020, 36(3): 283-288.
[11]	王凌星, 洪姗燕, 杨美丽, 黄红红. 丁苯酞对睡眠剥夺大鼠额叶小胶质细胞活化的影响^*[J]. 中国应用生理学杂志, 2020, 36(2): 106-110.
[12]	完建永, 张勇, 刘世强, 华田苗, 孙庆艳. 运动对胰岛素抵抗大鼠肝脏BIM信号通路的影响^*[J]. 中国应用生理学杂志, 2020, 36(2): 115-118.
[13]	姚良雪, 韩家鑫, 魏培韵, 侯思博, 何潇剑, 张瑞岭, 杜爱林. 丁苯酞对慢性酒精中毒大鼠海马、杏仁核H₂S/CBS通路及学习记忆能力的影响^*[J]. 中国应用生理学杂志, 2020, 36(2): 138-142.
[14]	窦丽. 游泳训练对高血压大鼠血压及血栓前状态分子的影响^*[J]. 中国应用生理学杂志, 2020, 36(2): 161-164.
[15]	苏艳红, 袁乾坤, 肖蓉, 陈娟, 李强, 张世超. 抗阻训练对增龄大鼠骨骼肌线粒体功能的影响^*[J]. 中国应用生理学杂志, 2020, 36(2): 165-170.